Lung Disease News

Latest medical research on lung disease. Learn about the symptoms of chronic obstructive pulmonary disease (COPD), emphysema, and lung cancer along with the latest treatment information.
Lung Disease News -- ScienceDaily
  1. Nanodecoys made from human lung spheroid cells (LSCs) can bind to and neutralize SARS-CoV-2, promoting viral clearance and reducing lung injury in a macaque model of COVID-19. By mimicking the receptor that the virus binds to rather than targeting the virus itself, nanodecoy therapy could remain effective against emerging variants of the virus.
  2. New research indicates that there are four molecular subtypes of bronchiolitis -- the most common lung infection in infants. Children with different subtypes face different risks of later developing asthma.
  3. Researchers report that Elovanoids, bioactive chemical messengers made from omega-3 very-long-chain polyunsaturated fatty acids, may block the virus that causes COVID-19 from entering cells and protect the air cells (alveoli) of the lung.
  4. Researchers have shown that even after lung tissue has been damaged, it may be possible to reverse fibrosis and promote tissue repair through treatment with microgel-coated mesenchymal stromal cells.
  5. When we inhale isolated coronavirus particles, more than 65 percent reach the deepest region of our lungs, new research has discovered, and more of these aerosols reach the right lung than the left.
  6. Researcher had previously discovered that the total mucin concentrations in the lungs are associated with COPD disease progression and could be used as diagnostic markers of chronic bronchitis, a hallmark condition for patients with COPD. They now report that one of these mucins, MUC5AC, is more closely and reliably associated with the development of COPD than is its brother, MUC5B.
  7. Scientists have found how platelets interacting with white blood cells contribute to the resolution of bacterial lung inflammation in mice. The results may help in the search for therapies to specifically regulate inflammation.
  8. The findings dash hopes that antimicrobials would benefit patients with life-threatening idiopathic pulmonary fibrosis. The trial, however, will still benefit the battle against the deadly lung disease, the researchers say.